T.E.M.S. Sluijs

T.E.M.S. Sluijs is a Researcher at Erasmus MC, specifically within the Department of Internal Medicine and the division of Medical Microbiology & Infectious Diseases. The individual is actively engaged in clinical and epidemiological research related to HIV, viral hepatitis, and antiretroviral therapies, contributing to major observational cohorts such as the ATHENA and D:A:D studies.

The research interests of T.E.M.S. Sluijs focus on HIV, antiretroviral therapy, viral hepatitis (B, C, and D), drug-drug interactions, and prospective cohort studies. These areas are central to understanding long-term outcomes in people living with HIV and improving diagnostic and therapeutic strategies.

The recent publications demonstrate a strong trend in evaluating real-world treatment effectiveness, patient experiences in healthcare delivery, the emergence of virulent HIV variants, and cancer risks associated with antiretroviral therapy timing. These works span high-impact journals such as Science, The Lancet HIV, and Annals of Internal Medicine, reflecting significant contributions to the field of infectious diseases.

Scientific Recognition and Impact:

• Research has been referenced in 4 Wikipedia pages
• Featured in 291 news outlets
• Discussed by 1,855 X (Twitter) users
• Reddited by 6 users
• Viewed by 170 Mendeley readers for a key 2022 Science article
• Part of large collaborative networks including ATHENA and D:A:D Study group

T.E.M.S. Sluijs participates in major multicenter research collaborations, particularly through the AIDS Therapy Evaluation in the Netherlands (ATHENA) Observational HIV Cohort and the Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group. These networks enable large-scale, prospective studies that inform clinical guidelines and public health policy. No formal advising or grant information is available in the provided text.